Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

October 2013 - FRMC

Department
Xtandi® (enzalutamide) - Oral Drug to Treat Castration-Resistant Prostate Cancer
10/23/2013
The FDA approved Xtandi® (enzalutamide) in August 2012 to treat patients with metastatic castration-resistant prostate cancer who previously failed treatment with docetaxel. The oral drug, marketed by Astellas Pharma, Inc. and Medivation,...
The FDA approved Xtandi® (enzalutamide) in August 2012 to treat patients with metastatic castration-resistant prostate cancer who previously failed treatment with docetaxel. The oral drug, marketed by Astellas Pharma, Inc. and Medivation,...
The FDA approved Xtandi®...
10/23/2013
First Report Managed Care
Efficacy of Long-Term Opioid Treatment
10/23/2013
Patients with chronic non-cancer pain maintained reductions in pain for at least 6 months, according to a review of randomized, controlled trials, single-arm, open-label trials, open-label extension trials, and epidemiologic trials.
Patients with chronic non-cancer pain maintained reductions in pain for at least 6 months, according to a review of randomized, controlled trials, single-arm, open-label trials, open-label extension trials, and epidemiologic trials.
Patients with chronic non-cancer...
10/23/2013
First Report Managed Care
Department
Lubiprostone to Treat Non-Cancer Pain and Opioid-Induced Constipation
10/23/2013
Patients with chronic non-cancer pain and opioid-induced constipation who took lubiprostone did not have an affect on opioid-induced analgesia.
Patients with chronic non-cancer pain and opioid-induced constipation who took lubiprostone did not have an affect on opioid-induced analgesia.
Patients with chronic non-cancer...
10/23/2013
First Report Managed Care
Breakthrough Pain and Cancer Costs
10/23/2013
Peoople with cancer and controlled, persistent pain had statistically significant higher mean unadjusted all-cause pharmacy costs if they had breakthrough pain. 
Peoople with cancer and controlled, persistent pain had statistically significant higher mean unadjusted all-cause pharmacy costs if they had breakthrough pain. 
Peoople with cancer and...
10/23/2013
First Report Managed Care
Managing Breakthrough Pain
10/23/2013
At the AAPM meeting, healthcare professionals discussed issues related to cancer-related pain during a satellite symposium titled Managing Breakthrough Pain Across the Provider Continuum. 
At the AAPM meeting, healthcare professionals discussed issues related to cancer-related pain during a satellite symposium titled Managing Breakthrough Pain Across the Provider Continuum. 
At the AAPM meeting, healthcare...
10/23/2013
First Report Managed Care
AUA Guidelines for Castrate-Resistant Prostate Cancer
10/23/2013
To help clinicians treat patients with castrate-resistant prostate cancer, the AUA released guidelines at its annual meeting to decide what options are best for numerous sub-types of the disease. 
To help clinicians treat patients with castrate-resistant prostate cancer, the AUA released guidelines at its annual meeting to decide what options are best for numerous sub-types of the disease. 
To help clinicians treat...
10/23/2013
First Report Managed Care
Complications Associated with Surgery for Bladder Cancer
10/23/2013
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of...
10/23/2013
First Report Managed Care
Treatment with Canagliflozin for 52 Weeks
10/23/2013
San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...
San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...
San Diego—After 52 weeks of...
10/23/2013
First Report Managed Care
Empagliflozin for Patients with Type 2 Diabetes and Hypertension
10/23/2013
San Diego—Patients with type 2 diabetes and hypertension who received 10 mg or 25 mg of empagliflozin once daily for 12 weeks had significant and clinically meaningful reductions in systolic and diastolic blood pressure, according to a phase...
San Diego—Patients with type 2 diabetes and hypertension who received 10 mg or 25 mg of empagliflozin once daily for 12 weeks had significant and clinically meaningful reductions in systolic and diastolic blood pressure, according to a phase...
San Diego—Patients with type 2...
10/23/2013
First Report Managed Care

Department

Conference Insider
Assessing the Misuse and Abuse of Opioids
10/23/2013
Five years ago, David Fishbain, MD, and co-authors published an article in Pain Medicine that examined issues related to opioids.
Five years ago, David Fishbain, MD, and co-authors published an article in Pain Medicine that examined issues related to opioids.
Five years ago, David Fishbain,...
10/23/2013
First Report Managed Care

Advertisement

Advertisement

Advertisement

FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

What's Trending?

News
Trump Open to Dropping Healthcare Provision in Senate Tax Bill: Aide
11/21/2017
A recent report stated that President Trump is open to leaving the ACA individual mandate repeal out of the tax reform bill if it will help the bill pass the Senate.
A recent report stated that President Trump is open to leaving the ACA individual mandate repeal out of the tax reform bill if it will help the bill pass the Senate.
A recent report stated that...
11/21/2017
First Report Managed Care
Analysis of 2015 Premiums as the Second Year of Marketplace Open Enrollment Approaches
11/03/2014
With open enrollment right around the corner, a report from the Kaiser Family Foundation examined changes in coverage under the Patient Protection and Affordable Care Act (ACA) moving into 2015.
With open enrollment right around the corner, a report from the Kaiser Family Foundation examined changes in coverage under the Patient Protection and Affordable Care Act (ACA) moving into 2015.
With open enrollment right...
11/03/2014
First Report Managed Care
News
Massachusetts Sues J&J Over Risperdal Marketing Practices
08/04/2011
08/04/2011
First Report Managed Care
News
FDA Approves Drug for Schizoaffective Disorder
11/15/2014
The FDA approved paliperidone palmitate, an atypical long-active antipsychotic, manufactured by Janssen Pharmaceuticals, Inc, for the treatment of schizoaffective disorder.
The FDA approved paliperidone palmitate, an atypical long-active antipsychotic, manufactured by Janssen Pharmaceuticals, Inc, for the treatment of schizoaffective disorder.
The FDA approved paliperidone...
11/15/2014
First Report Managed Care
News
Patient Assistance Program Improves Outcomes for Low-Income RA Patients
11/07/2017
According to research at the ACR/ARHP 2017 Annual Meeting, a patient assistance program and dedicated health care team within a community clinic setting can benefit low-income patients with accessing treatment and high cost biologics.
According to research at the ACR/ARHP 2017 Annual Meeting, a patient assistance program and dedicated health care team within a community clinic setting can benefit low-income patients with accessing treatment and high cost biologics.
According to research at the...
11/07/2017
First Report Managed Care

Video Insights

Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care
Farrukh Awan, MD
Videos
Promising Therapies and Clinical Trials for Chronic Lymphocytic Leukemia
08/14/2024
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights promising therapies and clinical trials within the field of chronic lymphocytic leukemia (CLL).
Farrukh Awan, MD, highlights...
08/14/2024
Journal of Clinical Pathways
Hayward
Videos
Evolving Health Care Contact Centers Into Drivers of Value-Based Care
07/31/2024
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact...
07/31/2024
First Report Managed Care
Lucille Accetta Headshot
Videos
Enhancing Patient Medication Adherence: Insights and Strategies From Asembia 2024
06/11/2024
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health...
06/11/2024
First Report Managed Care
Melissa Andel, Principal, CommonHealth Solutions, LLC
Videos
Navigating the Impact of the Inflation Reduction Act: Implications for Payers, Patients, and Manufacturers
05/24/2024
Melissa Andel, Principal, CommonHealth Solutions, LLC
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the...
05/24/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

October 2013 Volume 10 Issue 10

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement